Tumor-Specific Induction of Oxidative Stress with Dichloroacetate and Auranofin May Complement the Efficacy of PARP Inhibition in Cancer Control

Mark F. Mc Carty
Catalytic Longevity, 7831 Rush Rose Dr., Apt. 316, Carlsbad, CA 92009, USA

*Corresponding author: Mark F. Mc Carty, Catalytic Longevity; 7831 Rush Rose Dr. Apt. 316, Carlsbad, CA 92009, USA; Tel: 760-216-7272; Fax: 760-704-6379; E-mail: markfmccarty@gmail.com

Received date: January 26, 2015, Accepted date: February 15, 2015, Published date: February 20, 2015

Abstract

PARP inhibition can improve survival in cancer patients whose tumors have impaired capacity for homologous recombination, such as germ line or somatic mutations in BRCA. The efficacy of such therapy should be greater if the rate at which cancer cell DNA incurs single-strand breaks is enhanced. Since oxidative stress promotes formation of such breaks, measures which boost oxidative stress in cancer – preferable somewhat selectively – may be worthwhile adjuvants to PARP therapy. In the many cancers that express the Warburg phenomenon, dichloroacetate can promote increased mitochondrial generation of oxidants by directing more pyruvate to oxidation in the Krebs cycle. Concurrent administration of the arthritis drug auranofin could further enhance mitochondrial release of hydrogen peroxide by indirectly inhibiting peroxiredoxin-3, the chief mitochondrial source of peroxidase activity. The copper-chelating drug tetrathiomolybdate, employed in cancer therapy as an anti-angiogenic agent, can boost superoxide levels by diminishing activity of the copper-zinc-dependent cytosolic superoxide dismutase. Episodic intravenous infusion of high-dose ascorbate could also be employed to increase oxidative stress in the cancer and thereby complement PARP inhibitor therapy. The potential of dichloroacetate, auranofin, tetrathiomolybdate, and intravenous ascorbate to enhance the cancer-retardant efficacy of olaparib (or other PARP inhibitors) could be assessed in cell culture and rodent models.

Keywords: PARP; Olaparib; Oxidativestress; Dichloroacetate; Auranofin; Tetrathiomolybdate; Ascorbate

Cancer Therapeutic Potential of PARP Inhibition

PARP inhibitors are potentially useful for the control of cancers with impaired capacity for repair of double-strand breaks by homologous recombination (HR) [1]. These include cancers carrying genomic or somatic mutations of BRCA, or that for other reasons lack efficient HR. A key determinant of the success of PARP inhibitor therapy will be the rate at which single-strand DNA breaks are formed in cancer cells. By impeding the base excision repair mechanism required for remediation of single strand breaks, PARP inhibition increases the chance that double strand breaks will occur, most notably during S phase DNA replication. Capacity to repair such double strand breaks will be impaired in cells with inefficient HR, and unpaired double strand breaks can induce apoptosis via p53 signaling or other mechanisms.

Boosting Oxidative Stress in Cancers

Oxidative or nitrooxidative stress in cancer cells is capable of inducing single strand breaks, and many cancers are in a state of mild oxidative stress [2-4]. Measures which somewhat selectively up-regulate this oxidative stress in cancer cells can therefore be expected to potentiate the efficacy of PARP inhibitory therapy. In cancers that express an active Warburg phenomenon-reflecting constitutive activation of HIF-1 that drives glycolysis and inhibits mitochondrial oxidation of pyruvate by boosting pyruvate dehydrogenase kinase (PDK) expression – the PDK inhibitor dichloroacetate (DCA) boosts mitochondrial respiration and concomitant production of superoxide [5-7]. This increase in oxidative stress will tend to be cancer-specific, owing to higher PDK activity in many cancers, as well as the fact that cancer mitochondria tend to have dysfunctional respiratory chains, reflecting the genetic lability of cancer [8-10].

Mitochondrial release of hydrogen peroxide can be further boosted by inhibitors of thioredoxin reductase (TR), as thioredoxin-2 is the source of reductive power for peroxiredoxin-3, an antioxidant enzyme which contributes importantly to hydrogen peroxide disposal in mitochondria [11-13]. Peroxiredoxin-3 is c-Myc-inducible, and many cancers show increased expression of this enzyme [14-16]. The venerable anti-arthritis gold drug auranofin inhibits thioredoxin reductase potently, with a Ki of only 4 nM, reflecting an interaction between gold and the selenocysteine in its active site [17,18]. When added to cell cultures, 0.3 uM auranofin achieves a 50% inhibition of the mitochondrial fraction of TR [19]. The standard clinical regimen of this drug – usually 3 mg twice daily – may be sufficient to achieve partial inhibition of TR activity systemically.

Further Implications of Thioredoxin Reductase Inhibition

TR inhibition can be expected not only to boost intracellular levels of hydrogen peroxide, but to make this hydrogen peroxide more effective for modulating cell signaling pathways, as thioredoxin functions to reverse the oxidation of protein sulfhydryl groups which hydrogen peroxide induces [20,21]. In particular, hydrogen peroxide tends to activate the stress-activated MAP kinases, JNK and p38, via ASK-1; thioredoxin functions to inhibit ASK-1 activation [22]. When p53 is activated by DNA double-strand breaks-as occurs during PARP inhibitor therapy in p53-competant cells – JNK activity interacts with...
of TM-induced copper depletion do indeed decrease SOD1 activity in
somewhat responsive to PARP inhibition. 
15-20% of baseline levels-slows angiogenesis and cancer growth in some cases-though Phase III studies have not yet been done to confirm this [47-55]. 
Induction of single-strand breaks via oxidative stress could also be 
be expected to promote DNA single-strand breaks somewhat selectively in cancer cells, and hence would seem likely to boost the killing efficacy of concurrent PARP inhibition. However, intravenous ascorbate therapy can only be applied episodically, and PARP inhibition kills cancer cells primarily in S phase, when double-strand breaks develop during DNA synthesis. Hence, only a fraction of the tumor's cells would be targeted during a single ascorbate infusion session. That's why measures which achieve a continuous elevation of cancer oxidative stress—such as DCA and auranofin—might importantly complement the tumor kill achieved by episodic ascorbate infusions.

Summing Up

These considerations suggest that certain agents which are currently clinically available, and which can amplify cellular levels of reactive oxygen species—including DCA, auranofin, TM, and parenteral ascorbate—have the potential to boost the efficacy of PARP inhibition as a strategy for treating the many cancers which have an impaired capacity for homologous recombination. The rate at which PARP inhibitors induce apoptosis in such cancers will hinge on the rate at which single-strand breaks occur; oxidant stress can increase production of such breaks. Other oxidant-generating drugs currently in development—such as desclomol—may be worthy of evaluation in this respect once they become available [67]. This concept should be readily testable in cell culture studies, and in mice bearing human xenografts of cancers defective for homologous recombination.

To the extent that the measures recommended here can be expected to induce oxidative stress somewhat selectively in cancers, they would not be expected to increase the killing of healthy tissues, and hence should be rather well tolerated. The fact that baseline oxidant production is often greater in cancers than in healthy tissues, may imply that these agents will achieve a greater level of oxidant stress in such cancers. For example, whereas TM therapy would be expected to reduce SOD activity in all tissues, the impact of this on oxidant stress should be greater in cells that are making increased amounts of superoxide. Analogously, auranofin will boost hydrogen peroxide levels more dramatically in cells whose mitochondria have defective

Intravenous Ascorbate as an Adjuvant to PARP Inhibition

An additional pro-oxidative strategy with potential for boosting the efficacy of PARP inhibitor therapy is high-dose intravenous ascorbate, which has already been studied in ovarian cancer [61,62]. In millimolar concentrations that are achievable by high-dose infusion, ascorbate generates hydrogen peroxide in the extracellular space; cancers tend to be selectively susceptible to killing by this hydrogen peroxide, likely because their intracellular levels of superoxide and labile iron tend to be relatively high [62-66]. Ascorbate therapy could be expected to promote DNA single-strand breaks somewhat selectively in cancer cells, and hence would seem likely to boost the killing efficacy of concurrent PARP inhibition. However, intravenous ascorbate therapy can only be applied episodically, and PARP inhibition kills cancer cells primarily in S phase, when double-strand breaks develop during DNA synthesis. Hence, only a fraction of the tumor's cells would be targeted during a single ascorbate infusion session. That's why measures which achieve a continuous elevation of cancer oxidative stress—such as DCA and auranofin—might importantly complement the tumor kill achieved by episodic ascorbate infusions.
respiratory chains and hence make more superoxide—a common characteristic of cancer cells. And DCA could be expected to boost mitochondrial oxidation production most in cancer cells that have the Warburg phenotype and hence express elevated PDK activity.

In contrast, the use of PARP inhibitors to potentiate cytotoxic chemotherapy is likely to amplify the toxicity of the chemotherapy, as cytotoxic agents damage DNA in cancer cells and healthy cells alike; clinical experience in Phase I trials tends to bear this out [68,69]. Hence, there may be little net therapeutic gain in when PARP inhibitors are used during chemotherapy. (This however does not rule out the potential value of maintenance PARP inhibitor therapy as a follow-up to chemotherapy [70].)

References

1. Lee JM, Ledermann JA, Kohn EC (2014) PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 25: 32-40.
2. Mello Filho AC, Meneghini R (1984) In vivo formation of single-strand breaks in DNA by hydrogen peroxide is mediated by the Haber-Weiss reaction. Biochim Biophys Acta 781: 56-63.
3. Sawa T, Ohshima H (2006) Nitrative DNA damage in inflammation and its possible role in carcinogenesis. Nitric Oxide 14: 91-100.
4. McCarty MF, Barroso-Aranda J, Contreras F (2007) A two-phase strategy for treatment of oxidant-sensitive cancers. Med Hypotheses 69: 489-96.
5. Semenza GL (2007) HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 39: 231-4.
6. Sorokina LV, Pyatchanina TV, Didenko GV, Kaplia AA, Khyzhnyak SV (2011) The influence of sodium dichloroacetate on the oxidative processes in sarcoma 37. Exp Oncol 33: 216-21.
7. Kluzi J, Corazao-Rozas P, Toutl Y, Jendoubi M, Maire C et al (2012) Inactivation of the HIF-1alpha/PRDX3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res 72: 5035-47.
8. Akyin-Burns N, Ahmad IM, Zhu Y, Oberley LW, Spitz DR (2009) Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem J 418: 29-37.
9. Copeland WC, Wachman JT, Johnson FM, Penta JS (2002) Mitochondrial DNA alterations in cancer. Cancer Invest 20: 557-69.
10. Chen EL (2012) Mitochondrial dysfunction and cancer metastasis. J Bioenerg Biomembr 44: 619-22.
11. Cox AG, Winterbourn CC, Hampton MB (2010) Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. Biochem J 425: 313-25.
12. Chang TS, Cho CS, Park S, Yu S, Kang SW et al (2004) Peroxiredoxin III, a mitochondrial-specific peroxidase, regulates apoptotic signaling by mitochonridia. J Biol Chem 279: 41975-84.
13. Nossen L, Berggren M, Powis G (2003) Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res 1: 682-9.
14. Wonsey DR, Zeller KL, Dang CV (2002) The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci U S A 99: 6499-54.
15. Song IS, Kim HK, Jeong SH, Lee SR, Kim N et al (2011) Mitochondrial peroxiredoxin III is a potential target for cancer therapy. Int J Mol Sci 12: 7163-85.
16. Whitaker HC, Patel D, Howat WJ, Warren AW, Kay JD, Sangan T et al (2013) Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress. Br J Cancer 109: 983-93.
17. Gromer S, Arcscott LD, Williams CH Jr, Schirmer RH, Becker K (1998) Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273: 20096-101.
18. Rigobello MP, Messori L, Marcon G, Agostina CM, Bragadin M et al (2004) Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions. J Inorg Biochem 98: 1634-41.
19. Cox AG, Brown KK, Arner ES, Hampton MB (2008) The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 76: 1097-109.
20. Lo CM, Carroll KS (2013) The redox biochemistry of protein sulfonylation and sulfenylation. J Biol Chem 288: 26480-8.
21. Kalinina EV, Chernov NN, Saprin AN (2008) Biochemistry (Mosc ) 73: 1493-510.
22. Saitoh M, Nishihou H, Fujii M, Takeda K, Tobiume K et al (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-606.
23. Shi Y, Nikulsen F, Zawacki-Pankau J, Li H, Gabdoulline R et al (2014) ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ 21: 612-23.
24. Matthews JR, Wakesugi N, Virelizier JL, Yodoi J, Hay RT (1992) Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res 20: 3821-30.
25. Gebel S, Muller T (2011) The activity of NF-kappab in Swiss 3T3 cells exposed to aqueous extracts of cigarette smoke is dependent on thioredoxin. Toxicol Sci 59: 75-81.
26. Nakaya A, Sagawa M, Muto A, Uchida H, Ikeda Y et al (2011) The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity. Leuk Res 35: 243-9.
27. Lee CH, Jeon YT, Kim SH, Song YS (2007) NF-kappab as a potential molecular target for cancer therapy. Biofactors 29:19-35.
28. Kwak EL, Larochelle DA, Beaumont C, Torti SV, Torti FM (1995) Role of NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem 270: 15285-93.
29. Pham CG, Busici C, Zazzaroni F, Papa S, Jones J et al (2004) Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 119: 529-42.
30. Kiessling MK, Klemke CD, Kaminski MM, Galani IE, Krammer PH et al (2009) Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma. Cancer Res 69: 2365-74.
31. Bakker GR, Boyer RF (1986) Iron incorporation into apoferritin. The role of apoferritin as a ferric oxidase. J Biol Chem 261: 13182-5.
32. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G et al (2011) Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res 17: 783-91.
33. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A et al (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12: 852-61.
34. Chen Y, Zhang L, Hao Q (2013) Olaparib a promising PARP inhibitor in ovarian cancer therapy. Arch Gynecol Obstet 288: 367-74.
35. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15: 852-61.
36. Wang Y, Hill KS, Fields AP (2013) PKCiota maintains a tumor-initiating cell phenotype that is required for ovarian tumorigenesis. Mol Cancer Res 11: 1624-35.
37. Jatoi A, Radecki BC, Foster NR, Block MS, Grudem M et al (2014) A Mixed-Methods Feasibility Trial of Protein Kinase C iota Inhibition with
Auranofin in Asymptomatic Ovarian Cancer Patients. Oncology 88: 208-13.

Brewer GJ (2005) Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer. Curr Cancer Drug Targets 5: 195-202.

Khan G, Merajver S (2009) Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm. Expert Opin Investig Drugs 18: 541-8.

Zhang Z, Qiu L, Lin C, Yang H, Fu H et.al (2014) Copper-dependent and -independent hypoxia-inducible factor-1 regulation of gene expression. Metallomics 6: 1889-93.

Juarez JC, Betancourt O Jr, Pirie-Shepherd SR, Guan X, Price ML et.al (2006) Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase I. Clin Cancer Res 12: 4974-82.

Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM et.al (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62: 4834-9.

Bursac BN, Djordjevic AD, Vasiljevic AD, Milutinovic DD, Velickovic NA et.al (2013) Fructose consumption enhances glucocorticoid action in rat visceral adipose tissue. J Nutr Biochem 24: 1166-72.

Wang Y, Liu L, Du H, Nagaoka Y, Fan W et.al (2014) Transgenic overexpression of hexose-6-phosphate dehydrogenase in adipose tissue causes local glucocorticoid amplification and lipolysis in male mice. Am J Physiol Endocrinol Metab 306: E543-E551.

Varnai VM, Piasek M, Blanusa M, Juresa D, Saric M et.al (2003) Ascorbic acid supplementation does not improve efficacy of meso-dimercaptosuccinic acid treatment in lead-exposed suckling rats. Pharmacol Toxicol 93: 180-5.

Kumar P, Yadav A, Patel SN, Islam M, Pan Q et.al (2010) Tetrathiomolybdate inhibits head and neck cancer metastasis by decreasing tumor cell motility, invasiveness and by promoting tumor cell anoikis. Mol Cancer 9: 206.

Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M et.al (2000) Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 6: 1-10.

Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK et.al (2003) Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9: 1666-72.

Henry NL, Dunn R, Merjaver S, Pan Q, Pienta KJ et.al (2006) Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenic strategy in patients with hormone-refractory prostate cancer. Oncology 71: 168-75.

Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S (2008) A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 86: 383-9.

Gartner EM, Griffith KA, Pan Q, Brewer GJ, Henja GF et.al (2009) pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-fluorouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs 27: 159-65.

Lowndes SA, Adams A, Timms A, Fisher N, Smythe J et.al (2008) Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res 14: 7526-34.

Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G et.al (2013) A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naive prostate cancer. Urol Oncol 31: 581-8.

Schneider BJ, Lee JS, Hayman JA, Chang AC, Orringer MB et.al (2013) Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer. Invest New Drugs 31: 435-42.

Jain S, Cohen J, Ward MM, Kornhauser N, Huang E et.al (2013) Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse. Ann Oncol 24:491-8.

Lowndes SA, Sheldon HV, Cai S, Taylor JM, Harris AL (2009) Copper chelator ATN-224 inhibits endothelial function by multiple mechanisms. Microvasc Res 77: 314-26.

Donate I, Juarez JC, Burnett ME, Manuia MM, Guan X et.al (2008) Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224). Br J Cancer 98: 776-83.

Mello Filho AC, Meneghini R (1984) In vivo formation of single-strand breaks in DNA by hydrogen peroxide is mediated by the Haber-Weiss reaction. Biochim Biophys Acta 781: 56-63.

Smirnova M, Van KS, Sung P, Klein HL (2004) Effects of tumor-associated mutations on Rad34 functions. J Biol Chem 279: 24081-8.

Sajesh BV, Bailey M, Lichtenstejzin J, Hieter P, McManus KJ (2013) Synthetic lethal targeting of superoxide dismutase 1 selectively kills RAD54B-deficient colorectal cancer cells. Genetics 195: 757-67.

Ma Y, Chapman J, Levine M, Polireddy K, Drisko J et.al (2014) High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotheraphy. Sci Transl Med 6: 222ra18.

Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL et.al (2008) Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105: 11105-9.

Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC et.al (2007) Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A 104: 8749-54.

Parrow NL, Leshin JA, Levine M et.al (2013) Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal 19 :2141-56.

Ranzato E, Biffo S, Burlando B et.al (2011) Selective ascorbate toxicity in malignant mesothelioma: a redox Trojan mechanism. Am J Respir Cell Mol Biol 44: 108-17.

McCarty MF, Contreras F (2014) Increasing Superoxide Production and the Labile Iron Pool in Tumor Cells may Sensitize Them to Extracellular Ascorbate. Front Oncol 4: 249.

Hasinoff BB, Yadav AA, Patel D, Wu X (2014) The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II). J Inorg Biochem 137: 22-30.

Samol J, Ranson M, Scott E, Macpherson E, Carmichael J (2012) Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs 30: 1493-500.

Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummer S (2012) A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 18:2344-51.

Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH et.al (2014) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16 : 87-97.